These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26289223)

  • 1. What does the pharmacological future of treating chronic hepatitis C look like?
    Heil EL; Hynicka LM; Kottilil S; Tang L
    Expert Rev Clin Pharmacol; 2015; 8(5):605-22. PubMed ID: 26289223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C Virus: Current and Evolving Treatments for Genotype 4.
    Asselah T; Bourlière M
    Gastroenterol Clin North Am; 2015 Dec; 44(4):859-70. PubMed ID: 26600224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing the face of hepatitis C management - the design and development of sofosbuvir.
    Noell BC; Besur SV; deLemos AS
    Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy for hepatitis C genotype 3: moving forward.
    Buti M; Llaneras J; Riveiro-Barciela M; Esteban R
    J Viral Hepat; 2015 Sep; 22(9):683-90. PubMed ID: 25967352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future perspectives: towards interferon-free regimens for HCV.
    Gane E
    Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telaprevir: changing the standard of care of chronic hepatitis C.
    Rajani AK; Ravindra BK; Dkhar SA
    J Postgrad Med; 2013; 59(1):42-7. PubMed ID: 23525057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and Evolving Treatments of Genotype 1 Hepatitis C Virus.
    Alqahtani S; Sulkowski M
    Gastroenterol Clin North Am; 2015 Dec; 44(4):825-43. PubMed ID: 26600222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Direct Acting Antivirals treatment failed to cure a patient with chronic hepatitis C due to shifts of viral genotype.
    Lee SW; Yang SS; Lee TY; Yeh HZ; Lu IT; Chang CS
    J Gastrointestin Liver Dis; 2017 Jun; 26(2):205-206. PubMed ID: 28617895
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatitis C virus: standard-of-care treatment.
    Pawlotsky JM
    Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rapid evolution of treatment strategies for hepatitis C.
    Muir AJ
    Am J Gastroenterol; 2014 May; 109(5):628-35; quiz 636. PubMed ID: 24732866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C: How Good Are Real-Life Data and Do Generics Work.
    Tran AN; Lim JK
    Gastroenterol Clin North Am; 2020 Jun; 49(2):279-299. PubMed ID: 32389363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
    Welsch C; Jesudian A; Zeuzem S; Jacobson I
    Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of Hepatitis C Antiviral Therapy in Liver Transplant Recipients With Direct-acting Agents.
    Suraweera D; Saab EG; Tong MJ; Saab S
    Exp Clin Transplant; 2016 Jun; 14(3):243-51. PubMed ID: 27221717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.
    Florian J; Mishra P; Arya V; Harrington P; Connelly S; Reynolds KS; Sinha V
    Clin Pharmacol Ther; 2015 Oct; 98(4):394-402. PubMed ID: 26179495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new era of therapy for hepatitis C virus infection.
    Nyalakonda H; Utay NS
    Curr Opin Infect Dis; 2015 Oct; 28(5):471-8. PubMed ID: 26203851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future of hepatitis C therapy: development of direct-acting antivirals.
    Dore GJ; Matthews GV; Rockstroh J
    Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.